Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company, announced that it has acquired rights to Elyxyb (celecoxib oral solution) in the US and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
